Apollo Hospitals Enterprise Ltd
Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. As the nation’s first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country.
Apollo Hospitals has emerged as Asia’s foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies,
Primary Care & Diagnostic Clinics and several Retail Health models. [1]
- Market Cap ₹ 1,02,299 Cr.
- Current Price ₹ 7,115
- High / Low ₹ 8,100 / 6,001
- Stock P/E 61.2
- Book Value ₹ 632
- Dividend Yield 0.27 %
- ROCE 16.6 %
- ROE 18.4 %
- Face Value ₹ 5.00
Pros
- Company has delivered good profit growth of 33.7% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 21.5%
Cons
- Stock is trading at 11.2 times its book value
- Promoter holding has decreased over last quarter: -1.32%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of Nifty 50 BSE 500 BSE Healthcare BSE 100 BSE 200
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4,357 | 5,129 | 6,150 | 7,256 | 8,243 | 9,617 | 11,247 | 10,560 | 14,663 | 16,612 | 19,059 | 21,794 | 23,265 | |
| 3,681 | 4,392 | 5,465 | 6,522 | 7,442 | 8,548 | 9,656 | 9,420 | 12,474 | 14,548 | 16,665 | 18,761 | 19,940 | |
| Operating Profit | 676 | 737 | 684 | 734 | 801 | 1,070 | 1,591 | 1,140 | 2,189 | 2,065 | 2,394 | 3,033 | 3,324 |
| OPM % | 16% | 14% | 11% | 10% | 10% | 11% | 14% | 11% | 15% | 12% | 13% | 14% | 14% |
| 18 | 47 | 92 | 60 | 24 | 26 | 222 | 103 | 368 | 75 | 123 | 222 | 256 | |
| Interest | 119 | 118 | 180 | 257 | 295 | 327 | 533 | 449 | 379 | 381 | 449 | 458 | 442 |
| Depreciation | 168 | 212 | 264 | 314 | 359 | 396 | 620 | 573 | 601 | 615 | 687 | 758 | 828 |
| Profit before tax | 407 | 455 | 332 | 222 | 171 | 373 | 660 | 221 | 1,578 | 1,144 | 1,380 | 2,039 | 2,309 |
| Tax % | 25% | 29% | 29% | 41% | 65% | 47% | 34% | 38% | 30% | 22% | 32% | 26% | |
| 315 | 335 | 235 | 131 | 60 | 200 | 432 | 137 | 1,108 | 844 | 935 | 1,505 | 1,729 | |
| EPS in Rs | 22.77 | 24.43 | 16.99 | 15.88 | 8.44 | 16.96 | 32.70 | 10.46 | 73.42 | 56.97 | 62.50 | 100.56 | 116.28 |
| Dividend Payout % | 25% | 24% | 35% | 38% | 59% | 35% | 18% | 29% | 16% | 26% | 26% | 13% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 14% |
| 3 Years: | 14% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 34% |
| 3 Years: | 18% |
| TTM: | 41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 23% |
| 3 Years: | 18% |
| 1 Year: | -2% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 72 | 72 | 72 | 72 | 72 | 72 |
| Reserves | 2,907 | 3,102 | 3,262 | 3,244 | 3,182 | 3,264 | 3,270 | 4,531 | 5,551 | 6,126 | 6,864 | 8,140 | 9,021 |
| 1,344 | 1,992 | 2,834 | 3,125 | 3,427 | 3,673 | 3,596 | 4,160 | 4,068 | 4,332 | 5,333 | 7,864 | 7,987 | |
| 1,029 | 1,296 | 1,195 | 1,665 | 1,917 | 2,159 | 4,354 | 2,629 | 3,570 | 3,886 | 4,474 | 4,568 | 4,870 | |
| Total Liabilities | 5,350 | 6,459 | 7,360 | 8,103 | 8,596 | 9,166 | 11,289 | 11,392 | 13,261 | 14,416 | 16,742 | 20,644 | 21,950 |
| 2,681 | 3,244 | 3,997 | 4,591 | 4,773 | 4,982 | 7,432 | 6,778 | 8,296 | 8,520 | 9,664 | 10,988 | 11,262 | |
| CWIP | 491 | 533 | 562 | 347 | 712 | 822 | 236 | 234 | 46 | 610 | 873 | 921 | 1,026 |
| Investments | 322 | 311 | 352 | 406 | 352 | 462 | 434 | 1,343 | 816 | 574 | 986 | 2,487 | 3,008 |
| 1,855 | 2,372 | 2,448 | 2,759 | 2,759 | 2,901 | 3,187 | 3,037 | 4,104 | 4,712 | 5,219 | 6,248 | 6,653 | |
| Total Assets | 5,350 | 6,459 | 7,360 | 8,103 | 8,596 | 9,166 | 11,289 | 11,392 | 13,261 | 14,416 | 16,742 | 20,644 | 21,950 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 373 | 470 | 597 | 623 | 537 | 905 | 1,293 | 1,265 | 1,696 | 1,377 | 1,920 | 2,136 | |
| -356 | -759 | -888 | -1,152 | -405 | -711 | -289 | -880 | -747 | -857 | -1,537 | -3,381 | |
| -63 | 392 | 330 | 477 | -108 | -215 | -910 | -340 | -792 | -633 | -311 | 1,317 | |
| Net Cash Flow | -46 | 103 | 39 | -52 | 24 | -20 | 94 | 44 | 158 | -113 | 72 | 73 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 43 | 36 | 38 | 37 | 39 | 33 | 46 | 44 | 49 | 48 | 51 |
| Inventory Days | 47 | 50 | 49 | 47 | 51 | 46 | 49 | 16 | 21 | 17 | 17 | 16 |
| Days Payable | 55 | 59 | 66 | 51 | 55 | 56 | 60 | 74 | 79 | 82 | 88 | 72 |
| Cash Conversion Cycle | 36 | 34 | 19 | 34 | 33 | 29 | 22 | -12 | -14 | -16 | -23 | -6 |
| Working Capital Days | 23 | 24 | 16 | 27 | 8 | -3 | -8 | -4 | 5 | -1 | -19 | -6 |
| ROCE % | 12% | 12% | 9% | 8% | 7% | 10% | 14% | 8% | 17% | 14% | 15% | 17% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 31 Dec
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 31 Dec
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 31 Dec
- Closure of Trading Window 26 Dec
-
Subject: Receipt Of Observation Letter From The BSE Limited ('BSE') In Relation To The Proposed Composite Scheme Of Arrangement Amongst Apollo Hospitals Enterprise Limited ('Company'), Apollo Healthco Limited ('Transferor Company 1'), Keimed Private Limited ('Transferor Company 2') And Apollo Healthtech Limited ('Resultant Company') And Their Respective Shareholders And Creditors ('Scheme'), Under Sections 230 To 232, And Other Applicable Provisions Of The Companies Act, 2013 Read With The Rules Made Thereunder.
Ref: Disclosure Under Regulation 30 And Other Applicable Provisions Of The SEBI (LODR) Regulations, 2015, As Amended ('Listing Regulations').
24 Dec - BSE observation letter (24 Dec 2025) on Apollo demerger/amalgamation; Apollo Healthtech listing subject to conditions.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
Jun 2025Transcript PPT
-
May 2025TranscriptAI SummaryPPT REC
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Apr 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Jun 2020Transcript PPT
-
Feb 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019Transcript PPT
-
Feb 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
Apr 2017Transcript PPT
-
Nov 2016TranscriptPPT
-
Feb 2016TranscriptPPT
-
Nov 2015TranscriptAI SummaryPPT
Business Segments
1) Healthcare Services (50% in H1 FY26 vs 55% in FY22):[1][2][3]
The company has a capacity of 10,200 beds in 73 hospitals located in India and overseas, out of which 8,767 beds are located in 45 owned hospitals, 643 beds in Day Surgery & Cradles and 790 beds are in 6 hospitals under management through operations and management contracts.